National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

valacyclovir
The hydrochloride salt of the L-valyl ester of the antiviral drug acyclovir. Orally administered, valacyclovir is rapidly converted to acyclovir which inhibits viral DNA replication after further conversion to the nucleotide analog acyclovir triphosphate by viral thymidine kinase, cellular guanyl cyclase, and a number of other cellular enzymes. Acyclovir triphosphate competitively inhibits viral DNA polymerase; incorporates into and terminates the growing viral DNA chain; and inactivates viral DNA polymerase. The greater antiviral activity of acyclovir against herpes simplex virus (HSV) compared with varicellla-zoster virus (VZV) is due to its more efficient phosphorylation by HSV thymidine kinase. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

US brand name:Valtrex



Previous:vaccine-sensitized draining lymph node cells, vaccinia virus (vvDD-CDSR), vaccinia-PSA-TRICOM vaccine, vaccinia-tyrosinase vaccine, Vagestrol
Next:Valcyte, valdecoxib, Valeriana officinalis extract, valganciclovir, valproic acid

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov